Diaryl thioether piperazine compounds, preparation methods and uses thereof
The invention relates to a diaryl thioether piperazine compound, a preparation method and use thereof. Specifically, the compound is a compound of Formula (I), wherein HX is C 10-20 fatty acid or pamoic acid.
1. A compound of Formula (II), or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof,
wherein,
X 1 is —(CH 2 ) n —;
Y is
Z is C 1-20 alkyl, C 6-10 aryl, C 5-10 heteroaryl, or C 5-10 heterocyclyl, wherein optionally each of the C 1-20 alkyl, C 6-10 aryl, C 5-10 heteroaryl and C 5-10 heterocyclyl is independently substituted with one or more R;
n is 1, 2, 3, 4 or 5; and
each R is independently F, Cl, Br, I, amino, hydroxy or C 1-6 alkyl.
2. The compound of claim 1 , wherein Z is C 1-20 alkyl, phenyl, C 6-8 aryl, C 5-8 heteroaryl, or C 5-8 heterocyclyl, wherein optionally each of the C 1-20 alkyl, phenyl, C 6-8 aryl, C 5-8 heteroaryl and C 5-8 heterocyclyl is independently substituted with one or more R;
n is 1, 2 or 3; and
each R is independently F, Cl, Br, I, amino, hydroxy or C 1-3 alkyl.
3. The compound of claim 1 having one of the following structures, or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof,
4. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier, an excipient, a diluent, an adjuvant, a vehicle or a combination thereof.
5. The pharmaceutical composition of claim 4 further comprising an additional therapeutic agent, wherein the additional therapeutic agent is used for treating depressive disorder.
6. A method for preparing the compound of claim 1 , comprising:
(1) contacting a compound of Formula (a) with a compound of Formula (b) to obtain a compound of Formula (c); and
(2) contacting the compound of Formula (c) with a compound of Formula (d) to obtain a compound of Formula (II),
wherein,
X 1 is —(CH 2 ) n —;
each R 1 is independently F, Cl, Br or I;
Z is C 1-20 alkyl, C 6-10 aryl, C 5-10 heteroaryl, or C 5-10 heterocyclyl, wherein optionally each of the C 1-20 alkyl, C 6-10 aryl, C 5-10 heteroaryl and C 5-10 heterocyclyl is independently substituted with one or more R;
n is 1, 2, 3, 4 or 5; and
each R is independently F, Cl, Br, I, amino, hydroxy or C 1-6 alkyl,
7. The method of claim 6 , wherein Z is C 1-20 alkyl, phenyl, C 6-8 aryl, C 5-8 heteroaryl, or C 5-8 heterocyclyl, wherein optionally each of the C 1-20 alkyl, phenyl, C 6-8 aryl, C 5-8 heteroaryl and C 5-8 heterocyclyl is independently substituted with one or more R;
n is 1, 2 or 3; and
each R is independently F, Cl, Br, I, amino, hydroxy or C 1-3 alkyl.
8. A method for treating depressive disorder in a patient comprising administering to the patient the compound of claim 1 ; and administering to the patient an additional therapeutic agent, wherein the additional therapeutic agent is used for treating depressive disorder.
9. A method for treating depressive disorder in a patient comprising administering to the patient the compound of claim 3 ; and administering to the patient an additional therapeutic agent, wherein the additional therapeutic agent is used for treating depressive disorder.
10. A method for treating depressive disorder in a patient comprising administering to the patient the pharmaceutical composition of claim 4 ; and administering to the patient an additional therapeutic agent, wherein the additional therapeutic agent is used for treating depressive disorder.
11. A method for treating depressive disorder in a patient comprising administering to the patient the pharmaceutical composition of claim 5 .